Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL RECOMBINANT PROTEIN DRUGS INDUSTRY
2.1 Summary about Recombinant Protein Drugs Industry
2.2 Recombinant Protein Drugs Market Trends
2.2.1 Recombinant Protein Drugs Production & Consumption Trends
2.2.2 Recombinant Protein Drugs Demand Structure Trends
2.3 Recombinant Protein Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Recombinant DNA
4.2.2 Recombinant RNA
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Pharmaceutical Industry
4.3.2 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Recombinant DNA
5.2.2 Recombinant RNA
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Pharmaceutical Industry
5.3.2 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Recombinant DNA
6.2.2 Recombinant RNA
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Pharmaceutical Industry
6.3.2 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Recombinant DNA
7.2.2 Recombinant RNA
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Pharmaceutical Industry
7.3.2 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Recombinant DNA
8.2.2 Recombinant RNA
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Pharmaceutical Industry
8.3.2 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Recombinant DNA
9.2.2 Recombinant RNA
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Pharmaceutical Industry
9.3.2 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Novo Nordisk
10.1.2 Amgen
10.1.3 Sanofi
10.1.4 Eli Lilly
10.1.5 Merck Serono
10.1.6 Ortho Biotech
10.1.7 Roche
10.1.8 Kyowa Hakko Kirin
10.1.9 Pharmingen
10.1.10 Abcam
10.1.11 GenSci
10.1.12 SL PHARM
10.1.13 Dongbao Pharm
10.1.14 Ankebio
10.1.15 NCPC
10.1.16 Heng Rui
10.2 Recombinant Protein Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Novo Nordisk
10.2.2 Amgen
10.2.3 Sanofi
10.2.4 Eli Lilly
10.2.5 Merck Serono
10.2.6 Ortho Biotech
10.2.7 Roche
10.2.8 Kyowa Hakko Kirin
10.2.9 Pharmingen
10.2.10 Abcam
10.2.11 GenSci
10.2.12 SL PHARM
10.2.13 Dongbao Pharm
10.2.14 Ankebio
10.2.15 NCPC
10.2.16 Heng Rui
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
